UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2012
Impax Laboratories, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-34263 | 65-0403311 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
30831 Huntwood Avenue, Hayward, CA | 94544 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:(510) 240-6000
Not Applicable |
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 7.01 | Regulation FD Disclosure. |
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit No. | Description | |||
99.1 | J.P. Morgan Healthcare Conference Presentation. |
1
Dated: January 9, 2012 | IMPAX LABORATORIES, INC. | |||
By: | /s/ Arthur A. Koch, Jr. | |||
Name: | Arthur A. Koch, Jr. | |||
Title: | Executive Vice President, Finance, and Chief Financial Officer | |||
Exhibit No. | Description | |||
99.1 | J.P. Morgan Healthcare Conference Presentation. |